View Clinical Trial (Medical Research Study)

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis. - NCT00442702-33313(Clinical Trial 164393)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Lauderdale Lakes
State:  
FL
Zip Code: 33313
Conditions: Anemia
Purpose: This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease who are not on dialysis and who are receiving subcutaneous darbepoetin alfa maintenance therapy. Patients will be randomized either to remain on darbepoetin alfa therapy as per local label, or to switch to monthly subcutaneous Mircera, at a starting dose of 120, 200 or 360 micrograms, depending on the weekly dose of darbepoetin alfa administered prior to the first dose of Mircera. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Study summary:
Criteria: Inclusion Criteria: - adult patients, >=18 years of age; - chronic kidney disease, not requiring dialysis; - receiving darbepoetin alfa maintenance therapy for >=8 weeks before screening, and during screening/baseline period. Exclusion Criteria: - overt gastrointestinal bleeding within 8 weeks before screening, or during screening/baseline period; - transfusion of red blood cells within 8 weeks before screening, or during screening/baseline period; - active malignant disease; - previous treatment with Mircera.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: August 16, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.